8-K: Absci Secures $64M, Extends Runway to 2028 Amid Q2 Loss

Absci Corporation announced its second quarter 2025 financial results, reporting an increased net loss and decreased revenue, but significantly strengthened its balance sheet with a $64 million capital raise, extending its cash runway into the first half of 2028.

Summary

• Absci Corporation reported a net loss of $30.6 million for the second quarter ended June 30, 2025, compared to a net loss of $24.8 million for the same period in 2024.
• Revenue for Q2 2025 was $0.6 million, a decrease from $1.3 million in Q2 2024.
• Research and development expenses increased to $20.5 million in Q2 2025 from $15.3 million in Q2 2024, primarily due to advancement of internal programs.
• Selling, general, and administrative expenses decreased to $8.5 million in Q2 2025 from $9.3 million in Q2 2024.
• Cash, cash equivalents, and short-term investments stood at $117.5 million as of June 30, 2025, down from $134.0 million on March 31, 2025.
• In July 2025, Absci raised approximately $64 million in gross proceeds through an underwritten public offering ($50 million) and its at-the-market facility ($14 million).
• The company now projects its existing cash, cash equivalents, and short-term investments will fund operations into the first half of 2028.
• The collaboration with Almirall was expanded with the election of a second target for dermatological indications, potentially yielding up to $650 million in milestone payments across two programs.
• Internal pipeline programs are advancing, with ABS-101 (anti-TL1A) in Phase 1, ABS-201 (anti-PRLR) on track for Phase 1/2a initiation in early 2026, and preclinical progress for ABS-301 (immuno-oncology) and ABS-501 (anti-HER2).

Sentiment

Score: 7

Explanation: While financial results for the quarter show increased losses and decreased revenue, the significant capital raise and extended cash runway into 2028 provide strong financial stability. The progress across multiple internal pipeline assets and expanded collaborations indicate strong operational momentum and future potential, outweighing the short-term financial performance.

Positives

• Successfully raised approximately $64 million in gross proceeds in July 2025, significantly strengthening the balance sheet.
• Extended cash runway into the first half of 2028, providing substantial financial stability for ongoing operations and pipeline development.
• Expanded the ongoing AI Drug Discovery collaboration with Almirall, including the election of a second target, with potential for up to $650 million in milestone payments.
• ABS-101 (anti-TL1A) Phase 1 clinical trial initiated in May 2025, with interim data readout anticipated in the second half of 2025.
• ABS-201 (anti-PRLR) is on track to enter Phase 1/2a clinical trial in early 2026, with potential for interim efficacy readout in the second half of 2026, addressing a large unmet medical need in androgenetic alopecia.
• Preclinical data for ABS-101 supports a superior immunogenicity profile and extended half-life, suggesting potential for convenient infrequent dosing (Q8W-Q12W).
• ABS-201 demonstrated superior efficacy compared to 5% topical minoxidil in a 21-day hair regrowth model and shows a >3x extended half-life in NHPs compared to HMI-115.
• Progressing on key initiatives in strategic collaboration with AMD to scale Absci's AI Drug Creation platform, following AMD's $20 million strategic equity investment.
• Anticipate signing one or more new partnerships, including with a Large Pharma company, in 2025.

Negatives

• Revenue decreased to $0.6 million in Q2 2025 from $1.3 million in Q2 2024.
• Net loss increased to $30.6 million in Q2 2025 from $24.8 million in Q2 2024.
• Research and development expenses increased significantly to $20.5 million in Q2 2025 from $15.3 million in Q2 2024, contributing to the increased net loss.

Risks

• Risks and uncertainties relating to obtaining and maintaining necessary approvals from the FDA and other regulatory authorities.
• Challenges in replicating in clinical trials promising or positive results observed in preclinical studies.
• Dependence on third parties to support internal asset programs, including for the manufacture and supply of preclinical and clinical supplies.
• Ability to effectively collaborate on research, drug discovery, and development activities with partners or potential partners.
• Existing and potential partners' ability and willingness to pursue the development and commercialization of programs or product candidates under partnership agreements.
• Overall market conditions and regulatory developments that may affect company and partner activities.

Future Outlook

Absci anticipates continued advancement of its internal pipeline, with ABS-101 Phase 1 interim data expected in 2H 2025 and ABS-201 Phase 1/2a initiation in early 2026 with potential interim efficacy readout in 2H 2026. The company also expects to sign one or more new partnerships, including with a Large Pharma company, in 2025. The recent capital raise is expected to fund operations into the first half of 2028.

Management Comments

• "The past few months have been a period of strong execution for Absci, and we are positioned to build on this momentum."
• "ABS-101 is advancing through clinical trials, ABS-201 is on track to enter the clinic early next year, and we recently announced a key milestone in our collaboration with Almirall."
• "With a strengthened balance sheet and runway into the first half of 2028, we are well positioned to deliver on our mission."

Industry Context

Absci operates in the rapidly evolving biopharmaceutical sector, leveraging generative AI for drug discovery. The company's focus on difficult-to-drug targets and unmet medical needs, such as androgenetic alopecia (a market with approximately 80 million patients in the U.S. alone and limited innovation since the 1990s), positions it in high-potential areas. Its AI-driven platform aims to accelerate drug development timelines and improve success rates, aligning with broader industry trends towards AI/ML integration in R&D. The expansion of its collaboration with Almirall and ongoing strategic partnership with AMD highlight the increasing importance of cross-industry collaborations in advancing therapeutic innovation.

Comparison to Industry Standards

• ABS-101 (anti-TL1A) is designed to achieve superior therapeutic properties compared to first-generation clinical competitors like Merck's MK-7240, Roche's RVT-3101, and Sanofi's TEV-48574, particularly in terms of higher affinity/potency, binding to both monomer and trimer TL1A, lower immunogenicity potential, and more convenient dosing (Q8W to once quarterly vs. Q2W/Q4W for competitors).
• ABS-201 (anti-PRLR) demonstrates superior efficacy against 5% topical minoxidil in a 21-day hair regrowth model and shows a >3x extended half-life in NHPs compared to HMI-115, suggesting potential for significantly less frequent dosing (2-3 doses over 6 months vs. 6-12+ doses for HMI-115). Its profile aims to address the lack of innovation in androgenetic alopecia treatments since the last FDA approval in 1997.
• ABS-501 (anti-HER2) AI-designed antibodies show efficacy against trastuzumab-resistant xenograft tumors, offering a potential alternative or post-Enhertu treatment option for HER2-positive cancers, addressing a key unmet need for less toxic and effective therapies after Enhertu progression.

Stakeholder Impact

• **Shareholders:** The capital raise and extended cash runway reduce immediate dilution risk and provide confidence in the company's ability to fund its pipeline, despite the increased net loss. Future milestone payments from collaborations could provide significant value.
• **Patients:** Advancement of pipeline assets like ABS-101 for IBD and ABS-201 for androgenetic alopecia offers potential new, more effective, and convenient treatment options for significant unmet medical needs.
• **Employees:** Continued investment in R&D and pipeline advancement suggests stability and growth opportunities within the company.
• **Partners (Almirall, AMD):** Expanded collaborations and ongoing progress reinforce the value of Absci's AI platform and its potential to accelerate drug discovery for partners.

Next Steps

• Phase 1 interim data readout for ABS-101 expected in the second half of 2025.
• Phase 1b/2a study initiation for ABS-101 anticipated in the first half of 2026.
• Initiation of a Phase 1/2a clinical trial for ABS-201 anticipated in early 2026.
• Potential for an interim efficacy readout for ABS-201 in the second half of 2026.
• Anticipate signing one or more new partnerships, including with a Large Pharma company, in 2025.
• Continued preclinical development and further exploration of ABS-301's therapeutic potential.
• Continued progress on key initiatives in strategic collaboration with AMD.
• Continued focus on investments and operations on advancing internal pipeline programs, alongside current and future partnered programs, while achieving ongoing platform improvements and operational efficiencies.

Key Dates

Recommendation

While the reported quarterly financial results show a decline in revenue and an increase in net loss, the significant capital raise of $64 million and the extension of the cash runway into the first half of 2028 provide crucial financial stability and reduce immediate funding concerns. The company's pipeline is advancing with key milestones anticipated, including clinical trial readouts and new partnerships. The operational progress, particularly in the Almirall collaboration and the promising preclinical data for ABS-101 and ABS-201, indicates strong long-term potential. However, the current financial performance and the inherent risks of clinical-stage biopharmaceutical development suggest a 'hold' position, allowing investors to monitor the upcoming clinical data and partnership developments before making a more definitive investment decision.

Keywords

Biopharmaceutical, Generative AI, Drug Discovery, Clinical-stage, SEC Filing, Financial Results, Pipeline, Antibody Therapeutics, TL1A, PRLR, Immuno-oncology, HER2, Capital Raise, Almirall, AMD, Biologics, Androgenetic Alopecia, Inflammatory Bowel Disease